Jounce Therapeutics Inc. (JNCE)
$1.88
$0.00 (0.00%)As on 05-May-2023 09:30EDT
Market cap
$102 Mln
Revenue (TTM)
$82 Mln
P/E Ratio
--
P/B Ratio
0.3
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$-102 Mln
-
ROE
-0.3 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
0.6
-
Debt to Equity
0.1
-
Book Value
$3.5
-
EPS
$-1
-
Face value
--
-
Shares outstanding
52,635,500
9 Years Aggregate
CFO
$-185.60 Mln
EBITDA
$-116.18 Mln
Net Profit
$-225.38 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Jounce Therapeutics (JNCE)
| 69.4 | 0.5 | 55.4 | -64.0 | -28.3 | -37.8 | -- |
|
BSE Sensex*
| -9.7 | -0.2 | -7.0 | -6.4 | 7.4 | 8.6 | 11.7 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2022
|
2021
|
2020
|
2019
|
2018
|
|---|---|---|---|---|---|
|
Jounce Therapeutics (JNCE)
| -86.7 | 19.3 | -19.8 | 159.1 | -73.4 |
|
S&P Small-Cap 600
| -17.4 | 25.3 | 9.6 | 20.9 | -9.7 |
|
BSE Sensex
| 4.4 | 22.0 | 15.8 | 14.4 | 5.9 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Shareholding Pattern
View DetailsAbout Jounce Therapeutics (JNCE)
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. It develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the... Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors. The company is also developing JTX-8064, a monoclonal antibody that binds to leukocyte immunoglobulin like receptor B2, which is a cell surface receptor expressed on macrophages; and Pimivalimab, an anti-PD-1 antibody for combination therapy. In addition, its preclinical products are JTX-1484, a monoclonal antibody designed to reduce myeloid-mediated immune suppression; and JTX-2134, a monoclonal antibody designed to reduce myeloid-mediated immune suppression and activate T and NK cells. Jounce Therapeutics, Inc. was incorporated in 2012 and is headquartered in Cambridge, Massachusetts. Read more
-
Pres, CEO & Director
Dr. Richard Murray Ph.D.
-
Pres, CEO & Director
Dr. Richard Murray Ph.D.
-
Headquarters
Cambridge, MA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Jounce Therapeutics (JNCE)
What is the current share price of Jounce Therapeutics Inc (JNCE) Today?
The share price of Jounce Therapeutics Inc (JNCE) is $1.88 (NASDAQ) as of 05-May-2023 09:30 EDT. Jounce Therapeutics Inc (JNCE) has given a return of -28.3% in the last 3 years.
What is the current PB & PE ratio of Jounce Therapeutics Inc (JNCE)?
Since, TTM earnings of Jounce Therapeutics Inc (JNCE) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2022
|
-1.13
|
0.32
|
|
2021
|
-4.59
|
1.87
|
|
2020
|
-5.59
|
1.16
|
|
2019
|
5.22
|
1.70
|
|
2018
|
-4.06
|
1.07
|
What is the 52 Week High and Low of Jounce Therapeutics Inc (JNCE)?
The 52-week high and low of Jounce Therapeutics Inc (JNCE) are Rs -- and Rs -- as of 25-May-2026.
What is the market cap of Jounce Therapeutics Inc (JNCE)?
Jounce Therapeutics Inc (JNCE) has a market capitalisation of $ 102 Mln as on 05-May-2023. As per SEBI classification, it is a Small Cap company.
Should I invest in Jounce Therapeutics Inc (JNCE)?
Before investing in Jounce Therapeutics Inc (JNCE), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.